Citation for published version (APA):
Prior, K-K., Leisegang, M. S., Josipovic, I., Löwe, O., Shah, A. M., Weissmann, N., ... Brandes, R. P. (2016). CRISPR/Cas9-mediated knockout of p22phox leads to loss of Nox1 and Nox4, but not Nox5 activity. Redox Biology, 9, 287–295. https://doi.org/10.1016/j.redox.2016.08.013
CRISPR/Cas9-mediated knockout of p22phox leads to loss of Nox1 and Nox4, but not Nox5 activity

Kim-Kristin Prior, Matthias S. Leisegang, Ivana Josipovic, Oliver Löwe, Ajay M. Shah, Norbert Weissmann, Katrin Schröder, Ralf P. Brandes

PII: S2213-2317(16)30090-8
DOI: http://dx.doi.org/10.1016/j.redox.2016.08.013
Reference: REDOX456

To appear in: Redox Biology

Received date: 29 July 2016
Accepted date: 16 August 2016

Cite this article as: Kim-Kristin Prior, Matthias S. Leisegang, Ivana Josipovic Oliver Löwe, Ajay M. Shah, Norbert Weissmann, Katrin Schröder and Ralf P. Brandes, CRISPR/Cas9-mediated knockout of p22phox leads to loss of Nox and Nox4, but not Nox5 activity, Redox Biology, http://dx.doi.org/10.1016/j.redox.2016.08.013

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
CRISPR/Cas9-mediated knockout of p22phox leads to loss of Nox1 and Nox4, but not Nox5 activity

Kim-Kristin Prior¹², Matthias S. Leisegang¹², Ivana Josipovic¹², Oliver Löwe¹², Ajay M. Shah⁴, Norbert Weissmann³, Katrin Schröder¹², Ralf P. Brandes¹²,*

1 Institut für Kardiovaskuläre Physiologie, Goethe-Universität, 60590 Frankfurt am Main, Germany
2 German Center for Cardiovascular Research (DZHK), Partner site RheinMain, 60590 Frankfurt am Main, Germany
3 Excellence Cluster Cardio-Pulmonary System, Justus-Liebig-University 35390 Giessen, Germany, Member of the German Center for Lung Research (DZL)
4 King’s College London British Heart Foundation Centre, Cardiovascular Division, London, UK

* corresponding author
Institut für Kardiovaskuläre Physiologie
Fachbereich Medizin der Goethe-Universität
Theodor-Stern Kai 7
60590 Frankfurt am Main, Germany
Tel.: +49-69-6301-85321
Fax.: +49-69-6301-7668
Email: brandes@vrc.uni-frankfurt.de
Short title: CRISPR/Cas9-mediated p22phox knockout
Abstract (221 words)

The NADPH oxidases are important transmembrane proteins producing reactive oxygen species (ROS). Within the Nox family, different modes of activation can be discriminated. Nox1-3 are dependent on different cytosolic subunits, Nox4 seems to be constitutively active and Nox5 is directly activated by calcium. With the exception of Nox5, all Nox family members are thought to depend on the small transmembrane protein p22phox. With the discovery of the CRISPR/Cas9-system, a tool to alter genomic DNA sequences has become available. So far, this method has not been widely used in the redox community. On such basis, we decided to study the requirement of p22phox in the Nox complex using CRISPR/Cas9-mediated knockout. Knockout of the gene of p22phox, CYBA, led to an ablation of activity of Nox4 and Nox1 but not of Nox5. Production of hydrogen peroxide or superoxide after knockout could be rescued with either human or rat p22phox, but not with the DUOX-maturation factors DUOXA1/A2. Furthermore, different mutations of p22phox were studied regarding the influence on Nox4-dependent H$_2$O$_2$ production. P22phox Q130* and Y121H affected maturation and activity of Nox4. Hence, Nox5-dependent O$^-$ production is independent of p22phox, but native p22phox is needed for maturation of Nox4 and production of H$_2$O$_2$.

Keywords

NADPH oxidase, CYBA/p22phox, CRISPR/Cas9
Introduction

The Nox family of NADPH oxidases is an important source of reactive oxygen species (ROS). Through ROS, Nox enzymes play diverse roles in cellular signaling, regulation of gene expression, cell differentiation and posttranslational protein modifications (Bedard and Krause 2007). In mammals, seven members are expressed and grouped according to their mode of activation. Nox1, Nox2 and Nox3 are activated by an assembly with specific cytosolic proteins, which translocate to the plasma membrane. On the other hand, Nox5 and DUOX1 as well as DUOX2 (Dual oxidase 1 and 2) are directly activated by calcium in a EF-hand motif dependent manner. To our current knowledge, Nox4, in contrast, is constitutively active and ROS production of the enzyme is mainly controlled by its expression level (Brandes et al. 2014).

For DUOX1 or DUOX2, maturing factors are needed to achieve proper expression and activity. The small transmembrane protein p22phox/CYBA (Cytochrome B-245 Alpha Chain), was described to be essential for Nox1, Nox2 and Nox3 maturation, stabilization and activation (Zhu et al. 2006; Miyano and Sumimoto 2014; Nakano et al. 2007; Ambasta et al. 2004). P22phox has been found to interact with Nox4, indicating importance for Nox4 activity and localization (Ambasta et al. 2004; Martyn et al. 2006; Löhneysen et al. 2010). The exact site where p22phox interacts and activates Nox4 appears non-canocial with respect to Nox1, Nox2 or Nox3 (Löhneysen et al. 2008; Zhu et al. 2006). P22phox consists of two (or four) predicted transmembrane domains and an extended C-Terminus with a prolin-rich region, which is required for the assembly with p47phox or NoxO1 to membrane-bound Nox1, Nox2 and Nox3 (Zhu et al. 2006; Brandes et al. 2014). This feature is dispensable for Nox4 indicating a different role for the p22phox-Nox4 activation (Löhneysen et al. 2008; Kawahara et al. 2005). Mutations in p22phox are associated with a loss of function leading to severe immunodeficiency called chronic granulomatous disease (CGD), with inability to clear some pathogens and subsequent life threatening infections (Bu-Ghanim et al. 1990; Dinauer et al. 1990).

Further analysis of the structural and functional role of p22phox are necessary not just for understanding the Nox2-dependent pathogen defense, but also for the analysis of Nox4, as a protective cardiovascular enzyme.

In the kidney, the endothelium and fibroblasts, Nox4 is the predominantly expressed Nox homologue (Ago et al. 2005; Clempius et al. 2007; Geiszt et al. 2000). Nox4 is fundamentally different to the other Nox enzymes and exhibits a different dependency on p22phox. Approaches to study p22phox-Nox4 interaction like the p22phox mutant mouse nmf333 could only partially reveal the mechanisms underlying the relevant protein interaction (Nakano et al. 2008; Löhneysen et al. 2008). There is, however, no doubt that p22phox is important for Nox4 and changing the expression of this ubiquitously expressed protein alters H₂O₂ formation of most cells overexpressing Nox4 (Kawahara et al. 2005; Ambasta et al. 2004; Rezende et al. 2016). In previous work, Löhneysen et al. inserted mutations in p22phox which reduced Nox4-dependent H₂O₂ formation. A dual tryptophan motif in the N-terminal amino acids (aa) 6–11 was found necessary for Nox4 activity and localization. P22phox mutants of the first five -but not ten- aa did not impact on activity and are thus tolerated as well as deletion of aa after residue 130, which are involved in binding of p47phox or NoxO1 and activation of Nox1-3. In line with this, p22phox mutations in the C-terminal prolin-rich region (P156Q-P160Q) are tolerated for Nox4-derived H₂O₂ formation (Löhneysen et al. 2008; Kawahara et al. 2005). Point mutations in the putative membrane spanning domain are less well tolerated, e.g. non-conservative
exchange of arginine 90 (R90Q) abolished Nox4-dependent H₂O₂ production (Löhneysen et al. 2008; Roos et al. 1996).

Given that protein abundance of p22phox is largely controlled by posttranscriptional mechanisms and that a few studies on complete knockout of p22phox have been performed so far, we set out to study the requirement of p22phox in the Nox complex using Clustered regulatory interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9)-mediated knockout. CRISPR/Cas9-mediated genome editing offers a fast and easy way to manipulate genomes in cell culture requiring just a 20-nucleotide targeting sequence, called guide RNA (gRNA). In one variant of RNA-guided Cas9 nuclease, the BbsI enzyme-mediated knockout strategy, a pair of gRNAs have been successfully used to mediate microdeletions e.g. in the Homeobox protein EMX1 (Ran et al. 2013).

The p22phox gene (CYBA) is located on the long arm of chromosome 16 and consists of six exons with a total length of approx. 8500 nucleotides (Dinuador et al. 1990). As the first exon is found in all predicted variants of p22phox, gRNAs targeting or flanking the exon 1 were chosen for microdeletions. In this study CRISPR/Cas9-mediated p22phox HEK (human embryonic kidney cells) knockout cell lines were used to study the role of endogenous p22phox on the expression, maturation and activity of Nox4, but also Nox1 and Nox5. Moreover, truncated and modified p22phox variants with essential N-terminal and membrane domain mutations were analyzed in a constitutive and inducible Nox4-overexpressing and p22phox-deficient cellular system.

**Materials and Methods**

**Mutagenesis of p22phox**

The QuikChange II XL Site-Directed Mutagenesis Kit (#200521, Agilent) was used to mutate p22phox. Primers were designed with the web-based QuikChange Primer Design Program. Briefly, the plasmid coding for human p22phox (kindly provided by Thomas L. Leto, NIH) was used for mutant strand synthesis reaction with PfuUltra HF DNA polymerase (2.5 U/µl) according to the kit, followed by a DpnI (10 U/µl) digestion of the original strand. The mutated plasmid was transformed into XL10-Gold Ultracompetent cells, the generated plasmid was purified with the GenJet Plasmid Miniprep Kit (K0503, Thermo Scientific). Mutations were verified by sequencing. The following primers were used for the introduction of single amino acid mutation: CYBA A91stop 5’-GAG AGC AGG AGA TGG ACC TAC CGA ACA TAG TAA TTC CTG G-3’ and 5’-CCA GGA ATT ACT ATG TTC GGT AGG TCC TGC TCT C-3’; CYBA E52A 5’-CCA CAT GGC CCA CGC GAT CTG CCC CAT-3’ and 5’-ATG GGC CAG ATC GCG TGG GCC ATG TGG-3’; CYBA E12A 5’-CCA GCG CCT GCG CGT TGG CCC AC-3’ and 5’-ATG GG CAA CGC GCA GTA GGT AGC CAC GCA C-3’; CYBA G110stop 5’-CTG CTG GCC ACC ATC CTT TAG ACC GCC TGC-3’ and 5’-GCA GGC GTT CTA AAG GAT GGT GGC CAG CAG-3’; CYBA I110C 5’-CCG CCA GTA GGT GGA TGC CGC TCG C-3’ and 5’-CCA TTG CGA GCG GCT GCT ACC TAC TGG CGG-3’; CYBA Q130stop 5’-GAG AGC GTT GGC CAC TGC TGA TCT GGA TGA GAT TGG ACC ATC TTA AGT CAG CAC CCC TTC AAG ATC AGC AGT GCT CCT G-3’; CYBA R90Q 5’-GCG CGT CCT GCA T-3’ and 5’-ATG CAG GAC GCC CCC TTC AAG ATC AGC AGT GCT CCT G-3’; CYBA R90stop 5’-ATG CAG GAC GCC CTA AAG ATC GTA ATT CCT GGT AAA GGG C-3’; CYBA R90stop 5’-ATG CAG GAC GCC CTA AAG ATC GTA ATT CCT GGT AAA GGG C-3’; CYBA Y121H 5’-GAA TGA GGC AAT ATC TTA GCA TCT TGG GGC C-3’ as well Nox5 T493K 5’-CAG GAC CAC TGA TCT TGA AGG GTT GCC ACTC-3’ and 5’-GAG TGG CAC CCC TTC AAG ATC AGC AGT GCT CCT G-3’.
Cell culture

Human embryonic kidney 293 cells (HEK293) cells were obtained from ATCC (Manassas, VA, USA) and cultured in Modified Eagle's Medium (MEM, Gibco) supplemented with fetal calf serum (FCS; 8%), non-essential amino acids (0.1 mM), sodium pyruvate (1 mM) and gentamycin (50 μg/mL) in a humidified atmosphere (5% CO₂, 37 °C). HEK293 cells expressing human Nox4 with a tetracycline-inducible tet-on operator (Nox4-pDEST30) were kindly provided by K.-H. Krause (University of Geneva, Switzerland) (Serrander et al. 2007). Induction with 1 µg/mL tetracycline was performed for 24 h in HEK medium. HEK293 cells stably expressing human Nox4 (Nox4-HEK293) were generated as described before using lentiviral transfection and selection (Helmcke et al. 2009).

Transfection of Nox constructs

Transient transfection of HEK293 cells was performed using Lipofectamine 2000 (#11668027, ThermoFisher) and 0.75 μg/mL plasmid DNA according to the manufacturer’s instructions. Cells were kept in culture for 48 h. DUOX1 and DUOX2 plasmids were kindly provided by H. Grasberger (University of Michigan Medical School, Michigan).

Cloning of pHAGE2-NoxO1-NoxA1-Nox1 for transient overexpression

To clone NoxO1, NoxA1 and Nox1 as lentiviral triple overexpression plasmid under control of the human EF1a promoter, in which NoxO1 and NoxA1 are divided by a 2A peptide (F2A) and NoxA1 and Nox1 separated by an internal ribosome entry site (IRES), PCR amplifications of NoxO1, NoxA1 and Nox1 were performed from pCMV6-NoxO1 (NM_172167, #RC214973, Origene), pCMV6-NoxA1 (NM_001256067, #RC234211, Origene) and pCMV6-Nox1 (NM007052, #RC210426, Origene) Human cDNA ORF clones with the following primers: NoxO1 forward 5' -ATA GCG GCC GCC ATG GCA GGC CCC CGA TAC CCA GTT TCA GTG-3' and NoxO1 reverse 5' -ATT TGC TTTA GCC CCT GCT CCT CCG TCG TGG GTG GGT GCG GC-3', NoxA1 forward 5' -ATT AGC TAG CAT GCC TTC TCT GGG GGA CCT GGT GCG-3' and NoxA1 reverse 5' -ATT TGG ATC CTT AGG GCT TTA GCC CCT GCT GGT GGA CTC TCT GGG GGA CCT GGT GCG-3' and Nox1 forward 5' -ATT AGC TAG CAT GCC TTC TCT GGG GGA CCT GGT GCG-3' and Nox1 reverse 5' -ATT TGG ATC CTT AGG GCT TTA GCC CCT GCT GGT GGA CTC TCT GGG GGA CCT GGT GCG-3'. In parallel, a F2A region for placing between NoxO1 and NoxA1 was amplified with 5' -ATT TGC TAA GCA CGG GTT CGG GTG CGC CAG TAA AGC AGA C-3' and 5' -ATT TGC TAG CTG GAC CTG GAT TTG ACT CAT CAC CAC-3' from pHAGE2, which was a gift from G. Mostoslavsky (Boston University, MA, USA) (Somers et al. 2010). PCR products were cut in the following way to achieve a specific order of integration into pHAGE2: NoxO1 (NotI/BpiI (#ER0591, #ER0091, ThermoFisher), F2A (BpiI/NheI (#ER0091, #ER0972, ThermoFisher), NoxA1 (NheI/BamHI (#ER0972, #ER0055, ThermoFisher) and Nox1 (NdeI/BsaBI (#ER0581, #ER1711, ThermoFisher). In a first ligation reaction, pHAGE2 cut by BamHI/NotI (#ER0591, #ER0581, ThermoFisher) was used to be ligated with restricted NoxO1, F2A and NoxA1. This intermediate product was purified and further cut by NdeI/BsaBI (#ER0581, #ER1711, ThermoFisher) to be ligated in a second reaction with restricted Nox1. The final plasmid (pHAGE2-NoxO1-NoxA1-Nox1) was purified and sequenced.

Cloning of pHAGE2-Nox5 for stable overexpression

To clone pHAGE2-Nox5 for lentiviral overexpression under the control of the human EF1a promoter, Nox5 was amplified from pCMV6-Nox5 (NM_001184779) Human cDNA ORF Clone (#RC230471, Origene) with the following primers: 5' - ATT GCG GCC GCC ATG ACA TCT GGA GAC CCA GCC CAG AC-3' and 5' - ATT TGA TTA GGA TCT ATC GAC CTA GAA ATT CTC TTG GAA AAA TCT G-3'. pHAGE2 was a gift from Gustavo Mostoslavsky (Somers et al. 2010).
PCR product and pHAGE2 were cut with NotI/BsaBI (#ER0591, #ER1711, ThermoFisher) followed by ligation. Plasmid was purified and sequenced.

**Lentiviral Transfection of HEK293 cells with pHAGE2-Nox5**

Vesicular stomatitis virus (VSV) pseudotyped lentivirus was produced by transfection of HEK293T cells with pHAGE2-Nox5 in combination with HGPM2, Tat1B, Rev1B and VSV-G, which were a gift from Bianling Liu. Viral supernatants were collected, concentrated and snap-frozen after four days. Transfection of 70% subconfluent HEK293 with Nox5 viral particles was performed for 12 days, followed by clonal expansion.

**CRISPR/Cas9**

The web interface of CRISPR design (http://crispr.mit.edu/) was used to develop gRNAs. Off-target activity was evaluated additionally with Blastn (https://blast.ncbi.nlm.nih.gov/Blast.cgi). The pSpCas9(BB)-2A-Puro (PX459) v2.0 was a gift from Feng Zhang (Addgene plasmid # 62988) and used as cloning backbone. CRISPR/Cas9 was carried out similar as in Josipovic et al. 2016 and Ran et al. 2013. Briefly, phosphorylation and annealing was performed with the following oligonucleotides harboring a BbsI overhang: For (A) CYBA_1_Exon1 with 5’-CAC CGG GGT TGT CGC CAT G-3’ and 5’-AAA CCA TGG CGA CAC GAA CCC GGC C-3’, for (B) CYBA_2_Exon1 with 5’-CAC CGG GAC GCC AGC GCC TGG TCG T-3’ and 5’-AAA CAC GAA CAG GCG CTG GCG TCC C-3’, for (C) CYBA_3_Exon1 with 5’-CAC CGG GCC ATG TGG GCC AAC AAA C-3’ and 5’-AAA CGT TCG TTG GCC CCC ATG GCC C-3’, for (D) CYBA_1_Intron1 with 5’-CAC CGG TGC ACG TCA GGG ACG GTG G-3’ and 5’-AAA CCC ACC GTC CCT GAC GTG CAC C-3’, for (E) CYBA_2_Intron1 with 5’-CAC CGC GGG ACC TCG GGC TAC TTA C-3’ and 5’-AAA CGT AAG TAG CCC GAG TGC CCG C-3’, for (F) CYBA_3_Intron1 with 5’-CAC CGC CCA CCC TGT AAG TAG CCC G-3’ and 5’-AAA CCG GCC GTC TTA CAG GGT GGG C-3’ and for (G) CYBA_2_5’UTR with 5’-CAC CGC GGG GTT CGG CCG GGA GCG C-3’ and 5’-AAA CGC GCT CCC ACC CCG C-3’. Afterwards, BbsI (#FD1014, ThermoFisher) mediated digestion and T7 DNA ligase (#M0318L, NEB) directed ligation was performed followed by PlasmidSafe exonuclease treatment (#E3101K, Epicentre/Biozym) according to the manufacturers protocol. Plasmids were purified and sequenced. After transfection of the indicated combinations of pSpCas9(BB)-2A-Puro-gRNAs (Fig. 1B), positive cells were selected using puromycin (2 μg mL⁻¹) for five days prior to clonal expansion. Empty pSpCas9(BB)-2A-Puro was used as negative control.

**Determination of H₂O₂ production by luminol/HRP assay**

ROS production was measured as described before (Rezende et al. 2016; Prior et al. 2016). As probe, luminol (100 μM, #123072, Sigma) catalyzed by horseradish peroxidase (HRP, 1 U/ml, #P6782, Sigma) or L012 (250 μM, #120-04891, Wako) was used and measured in a TriStar² Multimode Reader (LB942, Berthold, Wildbad, Germany).

**Western Blot Analysis**

Triton-lysed samples were substituted with sample buffer (8.5% glycerin, 2% SDS, 6.25% TRIS/HCl pH 6.8, 20 mM DTT, 0.013% bromphenol blue) but not heat-denatured. As a reducing agent TCEP (tris(2-carboxyethyl)phosphine, Thermo Scientific) was used as described before (Schröder et al. 2012). Protein amounts were determined by Bradford protein assay. Proteins were separated by SDS-PAGE, substituted to Western analysis and detected by primary antibodies. Infra-red-fluorescent-labelled secondary antibodies were used and visualized in the Odyssey system (Licit, Bad Homburg, Germany). Nox4 was detected by an anti-Nox4 antibody (1:2000) reported by Anilkumar et al. (Anilkumar et al. 2008). Primary antibodies against Nox1 (Mox1, #sc-5821, 1:500), Nox5 (#sc-67006,
1:500) and p22phox (#sc-20781, 1:500) were purchased from Santa Cruz, β-Actin (#A1978, 1:2000) was obtained from Sigma.

RNA isolation and RT-qPCR

RNA was isolated with the RNA Mini-Kit (#BS67.311, Bio&Sell) according to the manufacturer’s instructions. Random hexamer primers (#C1181, Promega) and SuperScript III Reverse Transcriptase (RT, #1808044 ThermoFisher) were used for reverse transcription. A non-RT control was used. CDNA was used for semi-quantitative real-time PCR using iQ™ SYBR® Green Supermix (#1708880, BioRad) in a Mx3000P qPCR cycler (Agilent Technologies). Relative mRNA expression was normalized to RNA Polymerase IIa (POLR2A) and analyzed by the delta–delta-Ct method. Results are shown as relative to the corresponding control. Primer sequences are summarized in Table 1.

Statistical Analysis

Values are mean ± SEM (standard error of mean) if not otherwise indicated. Statistical analysis was carried out using Prism 3.02. For multiple testing ANOVA followed by post hoc testing (Bonferroni's Multiple Comparison Test) was used. Unless otherwise indicated, n indicates the number of individual experiments. Densitometry was performed using the Odyssey-software (Image studio lite 5.0) and normalized to corresponding reference protein β-Actin. A p-value of less than 0.05 was considered statistically significant (*p<0.05; **p<0.01; ***p<0.001).

Results

CRISPR/Cas9-mediated knockout of CYBA/p22phox

To study the role of endogenous p22phox on Nox4-dependent ROS formation, different guide RNAs (gRNAs) against the p22phox gene CYBA were designed (Fig. 1A, 1B). Seven different gRNAs were transfected into stable Nox4- (Fig. 1C; Nox4-HEK293) or tetracycline-inducible Nox4 HEK293 cells (Fig. 1D; tetNox4-HEK293) and CRISPR/Cas9-mediated knockout was validated by Western Blot. Whereas single gRNA usage resulted in p22phox protein reduction, most of the gRNA combinations displayed loss of p22phox in both HEK293 cell types (Fig. 1B, 1C, 1D). Complete loss of p22phox was achieved with a combination of three gRNAs (Fig. 1B&C; combination 17) or all seven gRNAs (Fig. 1B&C; combination 18). For the subsequent experiments, the most effective combinations were used with cells targeted with two or three gRNAs with the combinations 1, 4, 7, 8, 10 and 17.

Knockout of endogenous p22phox reduces Nox4-dependent H2O2 production, but not Nox4 expression

To test the influence of CRISPR/Cas9-mediated p22phox knockout on Nox4-dependent ROS production, Nox4 constitutively overexpressing (Fig. 2 left) and induced tetNox4-overexpressing HEK293 cells (Fig. 2 right, tetracycline 1 μg/mL, 24 h) were studied in the Luminol/HRP assay. P22phox and Nox4 mRNA as well as protein expression were studied in the cells subjected to ROS measurements (Fig. 2A, 2B, 2E, 2F, 2G, 2H). Deletion of p22phox resulted in a strong reduction of ROS production, and the extent of the effect correlated with the p22phox mRNA and protein expression but not with Nox4 mRNA or protein expression. Interestingly, the inhibitory effect on ROS formation appeared more prominent in the constitutively overexpressing than in the tet-inducible cells (Fig. 2C&D). Although deletion of p22phox lowered ROS formation, it certainly did not abolish it. This effect could potentially be a consequence of insufficient transfection efficiency.
Knockout of endogenous p22phox completely abolishes Nox4-dependent H₂O₂ production

To generate defined p22phox-deficient cells, Nox4- and tetNox4-HEK293 cells, harboring the most effectively reduced p22phox expression (gRNA combination 1 and combination 10), were clonally expanded. Multiple clones were tested on p22phox expression and H₂O₂ production and three of these were chosen for the subsequent studies. The three tested clones of either constitutive expressing Nox4-HEK293 cells (Fig. 3A) or tetracycline-induced tetNox4-HEK293 cells (Fig. 3B) displayed a complete loss of H₂O₂ production measured by luminol/HRP assay, in comparison to the empty vector control. Despite some unspecific bands in the Western blot, p22phox could not be detected in all three clonally expanded CRISPR/Cas9-knockout cell lines (C1 or C10). As the starting population of the clonal expansion with variable regarding Nox4 expression, Nox4 expression level also varied in the different p22phox-knockout cell lines. Hence, the H₂O₂ production is not dependent on Nox4 expression as seen in the Western blot, but on p22phox expression only. The clones C1-1 and C10-1 were used for all following experiments.

ROS production after p22phox knockout can be restored with p22phox, but not with DUOXA1 or DUOXA2

The clonally expanded p22phox knockout cells are an ideal tool for reconstitution experiments. Transfection of the cells with plasmids coding for human p22phox (hp22) as well as rat p22phox (rp22) restored the ROS production in Nox4-HEK293 cells as well as tetNox4-HEK293 cells (Fig. 4A&B). To test the hypothesis that DUOXA1/2 maturation factors may substitute p22phox, DUOXA1 (DA1) and/or DUOXA2 (DA2) were also transfected. Importantly, the DUOX maturation factors did not affect ROS formation (Fig. 4A&B) and therefore cannot substitute p22phox.

p22phox is required for Nox1-, but not Nox5-dependent O₂⁻ production

To test whether other Nox isoforms are also influenced by the knockout of endogenous p22phox, p22phox deficient cells were transiently transfected with either a NoxO1-NoxA1-Nox1 expressing plasmid or with a Nox5 plasmid. Despite knockout of p22phox, Nox5 transfected cells exhibited PMA (phorbol 12-myristate 13-acetate; 100 nM)-stimulated ROS production as detected by L012 chemiluminescence (Fig. 5A, CYBA KO1&2). A similar effect was observed in stably transduced Nox5-HEK293 cells subjected to CRISPR/Cas9 p22phox knockout with different combinations of gRNAs (1, 4, 7, 8, 10, 17) (Fig. 5B). In contrast, p22phox-deficiency completely abolished Nox1-dependent O₂⁻ production (Fig. 5C, CYBA KO1&2), whereas Nox1 expression was not changed (Fig. 5C). Thus, Nox5 but not Nox1-mediated ROS is independent of p22phox in contrast to Nox1 or Nox4.

Analysis of p22phox mutants and their effect on Nox4-dependent ROS production

To gain insights into the function of p22phox in Nox4-dependent ROS production, mutations were studied. First, c-terminal truncations were analyzed (Fig. 6A&B). Truncation beyond Q130 resulted in a complete loss of enzyme activity, whereas the protein truncated at Q130 still showed some ROS activity. Interestingly, this effect was more pronounced in the tetNox4-HEK293 cells as compared to the Nox4 stably expressing cells, potentially suggesting that the dynamic of Nox4 protein formation is relevant for this mutation. Importantly, these observations are in stark contrast to a previous publication, which reported that a p22phox-Q130 truncation was fully active (Löhneysen et al. 2008). Truncations at aa90, aa91 or aa110 were indispensable for Nox4 activity (Fig. 6A&B).

As several CGD patients carry the p22phox missense mutation R90, we also tested a R90Q mutant (Roos et al. 1996) on its effect on Nox4 (Fig. 6C&D). The mutation not only leads to a loss of Nox4-dependent H₂O₂ formation, it also exhibited reduced p22phox protein expression. Mutations of negatively charged amino acids at the beginning of the N-terminus (E5A, E12A) or aliphatic amino acid close to the predicted Nox1/2-p22phox interaction site (I120C) had no influence on Nox4-
dependent ROS production (Fig. 6C&D). Interestingly, the Y121H mutation, previously described by Banfi et al. in Cyba-deficient mice (Nakano et al. 2008) only resulted in ROS formation in the tetracycline-induced Nox4-HEK293 cells, whereas in the constitutive Nox4-HEK293 cells only a minimal effect on ROS production was achieved. None of the mutants had a dominant negative effect. I.e. transfection of the p22phox mutants into HEK cells overexpressing Nox4 but expressing endogenous p22phox had only a very minor effect on ROS formation (Sup. Fig. 1).

These results highlight the importance of R90, the transmembrane region aa90-130 and also indicate importance for Y121 and aa130-195 for Nox4 activity.

Discussion

In this study using CRISPR/Cas9-mediated knockout cell lines we demonstrate that p22phox deficit completely abolishes Nox1 and Nox4 but not Nox5-dependent ROS production. In contrast, expression levels of these Nox enzymes were independent of p22phox. The effect of the knockouts could be rescued with either human or rat p22phox, but not with the DUOX-maturation factors DUOXA1/A2. Truncation of p22phox till the amino acid 130 was without a functional consequence, while further truncation leads to a reduced function of the protein. Exchange of conserved negatively charged amino acids at the very N-terminus did not impact on Nox4-dependent ROS formation, whereas the R90Q mutant was not able to produce significant amounts of ROS. Surprisingly, the C-Terminus of p22phox was just dispensable in tetracycline-induced HEK293 cells. In constitutive Nox4-expressing cells, truncation of p22phox with Q130stop could not rescue the p22phox knockout. The same was observed for Y121H p22phox, which just restored the ROS producing capacity of tetracycline-induced Nox4. This might suggest that these parts of the protein are important during the de novo formation of the Nox-p22phox complex.

The functional interaction of the catalytically active Nox enzyme with p22phox on ROS formation is in line with previous work employing p22phox shRNA, siRNA or overexpression of Nox and p22phox (Kawahara et al. 2005; Löhneysen et al. 2008; Martyn et al. 2006). The rescue with either truncated Q130stop or Y121H p22phox was described for co-overexpression of p22phox and Nox4 (Löhneysen et al. 2008). This could be confirmed with the tetracycline-inducible Nox4 expression 24 h after the transfection with p22phox. Therefore, Nox4 is transcribed, translated and matured after the p22phox Q130stop or Y121H p22phox overexpression. In the constitutively expressing Nox4-HEK293 cells, Nox4 is already expressed in the absence of p22phox. Our data therefore suggest an involvement of the C-terminal part of p22phox in the maturation of the p22phox-Nox4 interaction. Since Nox4 is not dependent on cytosolic subunits to form a functional Nox complex the role of p22phox is rather stabilization then activation (Serrander et al. 2007; Peshavariya et al. 2009; Desai et al. 2014). Nox1, Nox2 and Nox3 maturation and glycosylation have also been described to be p22phox-dependent, but these isoforms are furthermore dependent on the direct activation by p22phox by the prolin-rich region in the C-terminus of p22phox (Nakano et al. 2007; Miyano und Sumimoto 2014). This region is dispensable for Nox4 activation as shown in the tetNox4-HEKs and co-expression studies by others (Kawahara et al. 2005; Löhneysen et al. 2008).

Zhu et al. described the dependence of Nox2 maturation on amino acids 6-142 (Zhu et al. 2006). Therefore we propose that also Nox4 maturation is dependent on the amino acids 6-130. In line with this, deletion of the first five amino acids, but not 11 amino acids, is tolerated by Nox4 as shown in a previous study (Löhneysen et al. 2008). Controversially, a peptide targeting the amino acids 6-11 (WAMWAN) did not inhibit Nox4-derived ROS production (Csányi und Pagano 2013). Furthermore, it was also reported that the D-Loop of Nox4 is responsible for the Nox4-p22phox activation
suggesting an ionic interaction (Löhneysen et al. 2010). We tested if substitution of inter-species conserved negatively charged glutamic acid in the N-terminal region influence Nox4 activity. Neither E5A nor E12A reduced Nox4 activity in p22phox-deficient HEK293 cells. Further studies on the structural relevance of the N-Terminus for Nox4 maturation and activity are thus needed to understand the mechanism underlying p22phox function.

For Nox1-3 a 1:1 p22phox heterocomplex formation is proposed for the activation and assembly of functional Nox complexes at the plasma membrane, whereas Nox5 forms homooligomers and does not require p22phox (Kawahara et al. 2011). In this and in other studies Nox4 overexpression yielded high ROS production with endogenous p22phox (Kawahara et al. 2005; Helmcke et al. 2009; Ambasta et al. 2004; Rezende et al. 2016). In HEK293 cells, co-overexpression of p22phox or its mutants did not further increase ROS production. This effect, however, is cell-type specific and in other cells, like COS-7 or PLB cells, basal p22phox mRNA expression might be insufficient to provide sufficient protein to the Nox enzyme. Maturation of Nox enzymes in general is a complex process and other proteins, like protein disulfide isomerase (Janiszewski et al. 2005) or Calnexin (Prior et al. 2016) also contribute to the process. Further studies are needed to understand the process in detail to dissect the precise mode of p22phox – Nox interaction.

In summary, we used CRISPR/Cas9 to reliably and rapidly alter genomic CYBA DNA sequences and induced a knockout of p22phox in two Nox4-overexpressing cell lines. We demonstrated that rapid deletion of p22phox is possible and that the activity of Nox1 and Nox4 but not Nox5 exclusively depends on p22phox.

**Acknowledgement**

The study was supported by the DFG Excellence Cluster “Cardiopulmonary System – ECCPS”, SFB 815 (TP A1 to RPBand SFB 834 (TPA2 to RPB) and the Faculty of Medicine, Goethe-Universität, Frankfurt am Main, Germany. AMS is supported by the British Heart Foundation.

**Conflict of interest**

The authors declare that they have no relevant financial, personal or professional relationships to disclose which could be perceived as a conflict of interest or as potentially influencing or biasing the authors’ work.

**Abbreviations**

CRISPR: Clustered regulatory interspaced short palindromic repeats
Cas9: CRISPR-associated protein 9
HEK293: Human embryonic kidney 293 cells
HRP: horseradish peroxidase
Nox4-HEK293: HEK293 cells stably expressing Nox4
PMA: phorbol 12-myristate 13-acetate
tetNox4-HEK293: HEK293 cells expressing Nox4 in tetracycline-inducible tet-on vector
Artwork and Tables with Captions

| Gen   | Sequence (5’-3’)          |
|-------|---------------------------|
| h POLR2A | **forward** GCACCACGTCCAATGACAT  |
|        | **reverse** GTGCGGCTGCTTCCATAA |
| h Nox4  | **forward** TCCGGAGCAATAAGCCAGTC  |
|        | **reverse** CCATTCGGATTTCCATGACAT |
| h CYBA  | **forward** TACTATGTTCGGGCCGTCCT  |
|        | **reverse** CACAGCGCCAGTAGGTA |

Literaturverzeichnis

Ago, Tetsuro; Kitazono, Takanari; Kuroda, Junya; Kumai, Yasuhiro; Kamouchi, Masahiro; Ooboshi, Hiroaki et al. (2005): NAD(P)H oxidases in rat basilar arterial endothelial cells. In: Stroke; a journal of cerebral circulation 36 (5), S. 1040–1046. DOI: 10.1161/01.STR.0000163111.05825.0b.

Ambasta, Rashmi K.; Kumar, Pravir; Griendling, Kathy K.; Schmidt, Harald H H W; Busse, Rudi; Brandes, Ralf P. (2004): Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. In: J. Biol. Chem. 279 (44), S. 45935–45941. DOI: 10.1074/jbc.M406486200.

Anilkumar, Narayana; Weber, Roberta; Zhang, Min; Brewer, Alison; Shah, Ajay M. (2008): Nox4 and nox2 NADPH oxidases mediate distinct cellular redox signaling responses to agonist stimulation. In: Arterioscler. Thromb. Vasc. Biol. 28 (7), S. 1347–1354. DOI: 10.1161/ATVBAHA.108.164277.

Bedard, Karen; Krause, Karl-Heinz (2007): The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. In: Physiol. Rev. 87 (1), S. 245–313. DOI: 10.1152/physrev.00044.2005.

Brandes, Ralf P.; Weismann, Norbert; Schröder, Katrin (2014): Nox family NADPH oxidases: Molecular mechanisms of activation. In: Free radical biology & medicine 76, S. 208–226. DOI: 10.1016/j.freeradbiomed.2014.07.046.

Bu-Ghanim, H. N.; Casimir, C. M.; Povey, S.; Segal, A. W. (1990): The alpha subunit of cytochrome b-245 mapped to chromosome 16. In: Genomics 8 (3), S. 568–570.

Clempus, Roza E.; Sorescu, Dan; Dikalova, Anna E.; Pounkova, Lily; Jo, Patricia; Sorescu, George P. et al. (2007): Nox4 is required for maintenance of the differentiated vascular smooth muscle cell phenotype. In: Arteriosclerosis, Thrombosis, and Vascular Biology 27 (1), S. 42–48. DOI: 10.1161/01.ATV.0000251500.94478.18.

Csányi, Gábor; Pagano, Patrick J. (2013): Strategies Aimed at Nox4 Oxidase Inhibition Employing Peptides from Nox4 B-Loop and C-Terminus and p22 (phox) N-Terminus: An Elusive Target. In: Int J Hypertens 2013, S. 842827. DOI: 10.1155/2013/842827.

Desai, Leena P.; Zhou, Yong; Estrada, Aida V.; Ding, Qiang; Cheng, Guangjie; Collawn, James F.; Thannickal, Victor J. (2014): Negative regulation of NADPH oxidase 4 by hydrogen peroxide-
inducible clone 5 (Hic-5) protein. In: The Journal of biological chemistry 289 (26), S. 18270–18278. DOI: 10.1074/jbc.M114.562249.

Dinauer, M. C.; Pierce, E. A.; Bruns, G. A.; Curnutte, J. T.; Orkin, S. H. (1990): Human neutrophil cytochrome b light chain (p22-phox). Gene structure, chromosomal location, and mutations in cytochrome-negative autosomal recessive chronic granulomatous disease. In: The Journal of clinical investigation 86 (5), S. 1729–1737. DOI: 10.1172/JCI114898.

Geiszt, M.; Kopp, J. B.; Varnai, P.; Leto, T. L. (2000): Identification of renox, an NAD(P)H oxidase in kidney. In: Proceedings of the National Academy of Sciences of the United States of America 97 (14), S. 8010–8014. DOI: 10.1073/pnas.130135897.

Helmcke, Ina; Heumüller, Sabine; Tikkanen, Ritva; Schröder, Katrin; Brandes, Ralf P. (2009): Identification of structural elements in Nox1 and Nox4 controlling localization and activity. In: Antioxidants & redox signaling 11 (6), S. 1279–1287. DOI: 10.1089/ARS.2008.2383.

Janiszewski, Mariano; Lopes, Lucia Rossetti; Carmo, Alípio O.; Pedro, Marcelo A.; Brandes, Ralf P.; Santos, Célio X. C.; Laurindo, Francisco R. M. (2005): Regulation of NAD(P)H oxidase by associated protein disulfide isomerase in vascular smooth muscle cells. In: J. Biol. Chem. 280 (49), S. 40813–40819. DOI: 10.1074/jbc.M509255200.

Josipovic, I.; Fork, C.; Preussner, J.; Prior, K. K.; Iloska, D.; Vasconez, A. E. et al. (2016): PAFAH1B1 and the lncRNA NONHSAT073641 maintain an angiogenic phenotype in human endothelial cells. In: Acta physiologica (Oxford, England). DOI: 10.1111/apha.12700.

Kawahara, Tsukasa; Jackson, Heather M.; Smith, Susan M. E.; Simpson, Paul D.; Lambeth, J. David (2011): Nox5 forms a functional oligomer mediated by self-association of its dehydrogenase domain. In: Biochemistry 50 (12), S. 2013–2025. DOI: 10.1021/bi1020088.

Kawahara, Tsukasa; Ritsick, Darren; Cheng, Guangjie; Lambeth, J. David (2005): Point Mutations in the Proline-rich Region of p22phox Are Dominant Inhibitors of Nox1- and Nox2-dependent Reactive Oxygen Generation. In: J. Biol. Chem. 280 (36), S. 31859–31869. DOI: 10.1074/jbc.M501882200.

Löhneysen, Katharina von; Noack, Deborah; Jesaitis, Algirdas J.; Dinauer, Mary C.; Knaus, Ulla G. (2008): Mutational analysis reveals distinct features of the Nox4-p22 phox complex. In: J. Biol. Chem. 283 (50), S. 35273–35282. DOI: 10.1074/jbc.M804200200.

Löhneysen, Katharina von; Noack, Deborah; Wood, Malcolm R.; Friedman, Jeffrey S.; Knaus, Ulla G. (2010): Structural insights into Nox4 and Nox2: motifs involved in function and cellular localization. In: Mol. Cell. Biol. 30 (4), S. 961–975. DOI: 10.1128/MCB.01393-09.

Martyn, Kendra D.; Frederick, Linda M.; Loehneysen, Katharina von; Dinauer, Mary C.; Knaus, Ulla G. (2006): Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. In: Cell. Signal. 18 (1), S. 69–82. DOI: 10.1016/j.cellsig.2005.03.023.

Miyano, K.; Sumimoto, H. (2014): N-Linked glycosylation of the superoxide-producing NADPH oxidase Nox1. In: Biochemical and biophysical research communications 443 (3), S. 1060–1065. DOI: 10.1016/j.bbrc.2013.12.086.

Nakano, Y.; Banfi, B.; Jesaitis, A.; Dinauer, M.; La Allen; Nauseef, W. (2007): Critical roles for p22phox in the structural maturation and subcellular targeting of Nox3. In: Biochemical Journal 403 (Pt 1), S. 97–108. DOI: 10.1042/BJ20060819.
Nakano, Yoko; Longo-Guess, Chantal M.; Bergstrom, David E.; Nauseef, William M.; Jones, Sherri M.; Bánfi, Botond (2008): Mutation of the Cyba gene encoding p22phox causes vestibular and immune defects in mice. In: J. Clin. Invest. 118 (3), S. 1176–1185. DOI: 10.1172/JCI33835.

Peshavariya, Hitesh; Jiang, Fan; Taylor, Caroline J.; Selemidis, Stavros; Chang, Catherine W. T.; Dusting, Gregory J. (2009): Translation-linked mRNA destabilization accompanying serum-induced Nox4 expression in human endothelial cells. In: Antioxidants & redox signaling 11 (10), S. 2399–2408. DOI: 10.1089/ars.2009.2579.

Prior, Kim-Kristin; Wittig, Ilka; Leisegang, Matthias S.; Groenendyk, Jody; Weissmann, Norbert; Michalak, Marek et al. (2016): The Endoplasmic Reticulum Chaperone Calnexin Is a NADPH Oxidase NOX4 Interacting Protein. In: J. Biol. Chem. 291 (13), S. 7045–7059. DOI: 10.1074/jbc.M115.710772.

Ran, F. Ann; Hsu, Patrick D.; Wright, Jason; Agarwala, Vineeta; Scott, David A.; Zhang, Feng (2013): Genome engineering using the CRISPR-Cas9 system. In: Nature protocols 8 (11), S. 2281–2308. DOI: 10.1038/nprot.2013.143.

Rezende, Flavia; Löwe, Oliver; Helfinger, Valeska; Prior, Kim-Kristin; Walter, Maria; Zukunft, Sven. et al. (2016): Unchanged NADPH Oxidase Activity in Nox1-Nox2-Nox4 Triple Knockout Mice: What Do NADPH-Stimulated Chemiluminescence Assays Really Detect? In: Antioxidants & redox signaling 24 (7), S. 392–399. DOI: 10.1089/ars.2015.6314.

Roos, D.; Boer, M. de; Kuribayashi, F.; Meischl, C.; Weening, R. S.; Segal, A. W. et al. (1996): Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. In: Blood 87 (5), S. 1663–1681.

Schröder, Katrin; Zhang, Min; Benkhoff, Sebastian; Mieth, Anja; Pliquett, Rainer; Kosowski, Judith et al. (2012): Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. In: Circ. Res. 110 (9), S. 1217–1225. DOI: 10.1161/CIRCRESAHA.112.267054.

Serrander, Lena; Cartier, Laetitia; Bedard, Karen; Banfi, Botond; Lardy, Bernard; Plastre, Olivier et al. (2007): NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. In: Biochem. J. 406 (1), S. 105–114. DOI: 10.1042/BJ20061903.

Somers, Aba; Jean, Jyh-Chang; Sommer, Cesar A.; Omari, Amel; Ford, Christopher C.; Mills, Jason A. et al. (2010): Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. In: Stem cells (Dayton, Ohio) 28 (10), S. 1728–1740. DOI: 10.1002/stem.495.

Zhu, Yanmin; Marchal, Christophe C.; Casbon, Amy-Jo; Stull, Natalie; Löhneysen, Katharina von; Knaus, Ulla G. et al. (2006): Deletion mutagenesis of p22phox subunit of flavocytochrome b558: identification of regions critical for gp91phox maturation and NADPH oxidase activity. In: The Journal of biological chemistry 281 (41), S. 30336–30346. DOI: 10.1074/jbc.M607191200.
GRAPHICAL ABSTRACT:
Fig. 1: CRISPR/Cas9-mediated knockout of p22phox in Nox4/tetNox4-HEK293 cells.
A, Schematic representation of the designed guide RNAs (gRNA) targeting 5’UTR (untranslated region; 1&7, green), exon 1 (2&3, red) or intron 1 (4-6, blue) of the p22phox gene (CYBA). Image taken from UCSC genome browser (http://genome-euro.ucsc.edu/index.html) is modified.
B, Used combinations of different gRNAs A-G for transfection of HEK293 cells.
C, D, Representative Western blot for p22phox, Nox4 and β-Actin protein expression in empty vector control cells (Vec) and after CRISPR/Cas9-mediated p22phox knockout with different combinations or single gRNAs as indicated and defined in B. Every combination (combi.) was tested in Nox4-HEK293 (C) or tetNox4-HEK293 cells (D).
Fig. 2: Nox4-dependent H$_2$O$_2$ production and expression in p22phox-CRISPR/Cas9 knockout Nox4/tetNox4-HEK293 cells.

A, B, Representative Western blot with densitometry for p22phox protein expression normalized to β-Actin in empty vector (Vec) control cells and after CRISPR/Cas9-mediated p22phox knockout (combinations of gRNAs: 1, 4, 8, 10, 17) in Nox4-HEK293 (A) or induced tetNox4-HEK293 cells (B). C, D, Relative luminol/HRP assay in controls (Vec) and after CRISPR/Cas9-mediated p22phox knockout (combi. 1, 4, 8, 10, 17) in Nox4-HEK293 (C) or tetNox4-HEK293 cells (D). CU (chemiluminescence unit) was normalized to protein amount (μg) and control (Vec). E-H, Normalized, relative mRNA level for CYBA (E, F) and NOX4 (G, H) in control (Vec) and CRISPR/Cas9-mediated p22phox knockout (combi. 1, 4, 8, 10, 17) in Nox4-HEK293 (E, G) or induced tetNox4-HEK293 cells (F, H).

n≥3, mean ± SEM, *p<0.05; **p<0.01; ***p<0.001 relative to the corresponding vector treated cells (Vec).
Fig. 3: Nox4-dependent H$_2$O$_2$ production in subclonal expanded p22phox-CRISPR/Cas9 knockout Nox4/tetNox4-HEK293 cells. Either Nox4-HEK293 (A) or induced tetNox4-HEK293 cells (B) were transfected with empty vector (Vec) or gRNA combination 1 or 10, selected with puromycin and subclonally expanded. Each clone is named according to the vector control (Vec) or gRNA combination (1 or 10) and ongoing number (e.g. C1-1). Relative luminol/HRP assay was performed in subclonally expanded control cells (Vec) or CRISPR/Cas9-mediated p22phox knockout (combinations 1 or 10) Nox4-HEK293 (A) or tetNox4-HEK293 cell lines (B). Also shown are representative Western blots for p22phox, Nox4 and β-Actin.

n≥3, mean ± SEM, ***p<0.001 relative to corresponding vector clones.
Fig. 4: Nox4-dependent H$_2$O$_2$ production in p22^phox^ CRISPR/Cas9 knockout Nox4/tetNox4-HEK293 cells. Either subclonally expanded p22phox knockout Nox4-HEK293 (C1-1 and C10-1; A) or tetNox4-HEK293 cells (C1-1 and C10-1; B) were transiently transfected (overexpression: OE) with human (hp22), rat p22phox (rp22) or DUOXA1 (DA1), DUOXA2 (DA2) or a combination of both (DA1/2). Relative luminol/HRP assay in Nox4-HEK293 (A) or induced tetNox4-HEK293 cells (B) was performed.

n=6, mean ± SEM, *p<0.05; **p<0.01; relative to the corresponding control cells.
Fig. 5: Nox1- or Nox5-dependent H$_2$O$_2$ production in p22phox-CRISPR/Cas9 knockout HEK293 cells.

A. p22phox-knockout HEK293 cells (KO) or control cells (Vec) were transiently transfected with control (Ctl) or human Nox5 overexpression (OE) plasmid and treated with PMA (100 nM, 30 min). Relative L012 assay of the transiently transfected cells was performed. Also shown are representative Western blots for p22phox, Nox5 and β-Actin.

B. Stably transduced Nox5-HEK293 cells were treated with empty vector (Vec) or different gRNAs combinations targeting p22phox (combi. 1, 4, 7, 8, 10, 17) and treated with PMA (100 nM, 30 min). Relative L012 assay was performed. Normalized, relative Western Blot for Nox5 and mRNA expression of p22phox (CYBA) are shown.

C. p22phox-deficient HEK293 cells (KO) or control cells (Vec) were transiently transfected with human Noxo1-Noxa1-Nox1 triple overexpression plasmid (OE) and treated with PMA (100 nM, 30 min). Relative L012 assay was performed.

n≥3, mean ± SEM, ***p<0.001.
Fig. 6: Nox4-dependent H₂O₂ production with p22phox mutants in p22phox-CRISPR/Cas9 knockout HEK293 cells.

Either subclonally expanded p22phox knockout (KO) Nox4-HEK293 (C1-1 and C10-1; A&C) or induced tetNox4-HEK293 cells (C1-1 and C10-1; B&D) were transiently transfected (overexpression: OE) with full-length human (hp22), truncated (⁎; stop (A&B)) or point mutated versions of p22phox (C&D). Relative luminol/HRP assay in Nox4-HEK293 (A&C) or induced tetNox4-HEK293 cells (B&D) was performed.

n=6, mean ± SEM, **p<0.01; ***p<0.001, relative to the corresponding p22phox (hp22) transfected cells.
SUPPL:

Sup. fig. 1: Nox4-dependent H2O2 production with p22phox mutants in control HEK293 cells.
Either subclonally expanded empty control vector treated Nox4-HEK293 (Vec-2; A&C) or tetNox4-HEK293 cells (Vec-3; B&D) were transiently transfected with full-length human (hp22), truncated (*; stop (A&B)) or point mutated versions of p22phox (C&D). Relative luminol/HRP assay in Nox4-HEK293 (A) or induced tetNox4-HEK293 cells (B) was performed.

n=6, mean ± SEM, relative to the corresponding p22phox (hp22) transfected cells.